Balance Cost, Speed & Translatability Through Smarter Tumor Model Selection to Advance Discovery, Accelerate Development & Improve Clinical Success
As oncology development becomes more complex, the challenge is no longer simply generating more data. It's determining which evidence provides enough confidence to progress an asset, secure investment, and improve the likelihood of clinical success. From ADCs and T-cell engagers to cell therapies, cancer vaccines, and next-generation immunotherapies, drug developers are under increasing pressure to demonstrate stronger translational relevance earlier while balancing speed, cost, and scientific rigor.
The 11th Tumor Models Summit San Francisco brings together the West Coast's leading oncology decision-makers across discovery, translational research, pharmacology, preclinical development, bioinformatics, and data science to benchmark how they're generating more predictive evidence, evaluating emerging model systems, and making smarter development decisions.
Through case studies, discussion-led sessions, and practical implementation insights, discover how leading organizations are de-risking programs earlier, strengthening candidate prioritization, and building stronger cases for clinical progression.
-
A great opportunity to discuss technical aspects, biological advantages and limitations of different approaches and tumor models, and share insights, challenges and potential solutions with colleagues involved in nonclinical and translational research.
Ana Krtolica, Chief Development Officer, Swiss Rockets
-
In this fast-paced scientific environment, sharing information at conferences is the most effective way to learn new models and hear the details of other scientists’ experiences.
Pamela Contag, Chief Executive Officer & Co-Founder, BioEclipse Therapeutics
-
A good chance to communicate with other people in the field and share our work to others and hopefully get some meaning feedback and also learn from others.
John Wang, Chief Scientific Officer, Kali Therapeutics
Explore the Full Event Guide
- Explore the full agenda focused on clinical translation, model selection and development risk reduction
- Discover how leading oncology teams are evaluating organoids, ex vivo systems, AI-enabled platforms and in vivo models
- Preview case studies from Amgen, Astellas, Pfizer, Eli Lilly and emerging biotech innovators
- Benchmark approaches to biomarker development, resistance modeling, and candidate prioritization
- Connect with the leaders responsible for oncology development strategy, portfolio decisions, and preclinical investment
Top Speakers
Sorry, we couldn't find any posts. Please try a different search.
Official Partners
Attending Companies Include:
Explore Related Events
Explore the Agenda
Discover how leading oncology teams are generating stronger evidence, improving translational confidence, and making better development decisions.
Partner With Us
Connect with the executives, heads, directors, and scientific leaders shaping oncology development strategy across the West Coast.
Join the Discussion
Benchmark your approach to model selection, candidate prioritization, resistance modeling, biomarker development, and translational decision-making.